ten-year follow-up survival of the medicine, angioplasty, or surgery study (mass-ii): a randomized...
TRANSCRIPT
![Page 1: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/1.jpg)
Ten-Year Follow-up Survival of the Medicine,
Angioplasty, or Surgery Study (MASS-II): a
Randomized Controlled Clinical Trial of Therapeutic
Strategies for Multivessel Coronary Artery Disease
Whady Hueb, Neuza Lopes, Bernard J. Gersh, Paulo R. Soares, Expedito E. Ribeiro,
Alexandre C. Pereira, Desiderio Favarato, Antonio Sérgio C. Rocha, Alexandre C.
Hueb and Jose A.F. Ramires
Heart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazil
![Page 2: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/2.jpg)
Competing Interests
• The authors declare no potential competing interest.
![Page 3: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/3.jpg)
• Compared to CABG treatment, PCI or MT is associated with
higher rates of angina and subsequent revascularization, but no
significant differences in mortality or rates of MI have been found.
• Revascularization therapy in stable multivessel coronary artery
disease (CAD) and preserved ventricular function remains
controversial.
BACKGROUND
![Page 4: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/4.jpg)
• To our Knowledge, there is no study that has ever compared
end points among these 3 therapeutic strategies for more than a
5-year follow-up period.
BACKGROUND
![Page 5: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/5.jpg)
• To compare 10-year follow-up survival of the medical treatment,
angioplasty, or surgical strategies among patients with stable
multivessel CAD and preserved ventricular function.
OBJECTIVE
![Page 6: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/6.jpg)
METHODS
RANDOMIZATIONRANDOMIZATION
ANGIOPLASTYANGIOPLASTY(BMS)(BMS)
MEDICAL TREATMENTMEDICAL TREATMENT(alone)(alone)
SURGERYSURGERY(on-pump CABG)(on-pump CABG)
Stable AnginaStable Angina
Multivessel Coronary Artery Disease Multivessel Coronary Artery Disease
Preserved Left Ventricular FunctionPreserved Left Ventricular Function
Surgeon / Interv. Cardiologist / Surgeon / Interv. Cardiologist / ClinicalClinical Cardiologist Team approval Cardiologist Team approval
Recruitment: May 1995 - May 2000 (Heart Institute - InCor)Recruitment: May 1995 - May 2000 (Heart Institute - InCor)
Hueb W., et al. Circulation 2007;115:1082-1089
![Page 7: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/7.jpg)
METHODS
• Primary end-point (composite):
✓ overall mortality,
✓ myocardial infarction,
✓ refractory angina requiring new revascularization
• Ten-Year Follow-Up
![Page 8: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/8.jpg)
• All analysis were done according to intention to treat principle.
• Sample size: power 80% and a two-side level of significance of
0.05% - 191 patients in each group.
• Statistical test: Chi-Square, log-rank test, ANOVA, Tukey
multiple-comparisons test, Cox’s regression and McNemar test.
Statistical Analysis
![Page 9: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/9.jpg)
RESULTS
Hueb W, et al. J Am Coll CardioI 2004; 43:1743-51
1465 patients non-randomized:
SurgerySurgery(n=203)(n=203)
Medical Treatment(n=203)
Angioplasty (n=205)
excluded 18.692 patients:
coronary <30% lesion - 5192
single coronary disease - 3531
previous CABG/PCI - 2908
valvar disease 2701
other - 4361
refused to participate in this trial or
refused the surgical procedure
Database: 20.769 coronary angiographies
Elegible: 2.076 patients(suitable to PCI-CABG)
MASS II MASS II Randomized: 611 patientsRandomized: 611 patients
![Page 10: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/10.jpg)
Demographic ProfileDemographic Profile
Male, (%)Male, (%)
Age (years) mean±SDAge (years) mean±SD
Medical HistoryMedical History
Previous MI, (%)Previous MI, (%)
Smoker, (%)Smoker, (%)
Hypertension, (%)Hypertension, (%)
Diabetes mellitus, (%)Diabetes mellitus, (%)
CCS class 2 or 3, (%)CCS class 2 or 3, (%)
6969
60±960±9
3939
3333
5555
3636
7878
MT(n = 203)
MT(n = 203)
7272
61±61±88
4141
3232
6363
2929
8585
CABG(n = 203)
CABG(n = 203)
6767
60±460±4
5252
2727
6060
2626
7676
PCI(n=205)
PCI(n=205)CharacteristicCharacteristic
0.4120.412
0.9590.959
0.0240.024
0.0130.013
0.2150.215
0.0620.062
0.0060.006
PP
BaselineBaseline Characteristics Characteristics ofof MASSMASS IIII
![Page 11: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/11.jpg)
Clinical Characteristics
- Metabolic Aspects -
MT PCI CABG
(n=203) (n=205) (n=203)
Total Cholesterol (mg/l) 222±39 220±41 214±42 0.063
LDLChol (mg/dl) 148±34 147±36 143±36 0.305
HDL Chol (mg/dl) 37±10 38±10 37±10 0.870
Triglicerides (mg/dl) 178±82 181±73 169±84 0.235
Glucose mg/dl) 139±68 128±60 122±44 0.062
PP
![Page 12: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/12.jpg)
Double-Vessel Disease, (%)
Triple-Vesel Disease, (%)
Proximal LAD disease, (%)
Mean ejection fraction (mean±DP)
Double-Vessel Disease, (%)
Triple-Vesel Disease, (%)
Proximal LAD disease, (%)
Mean ejection fraction (mean±DP)
MT
(n = 203)
MT
(n = 203)
CABG
(n = 203)
CABG
(n = 203)
PCI
(n = 205)
PCI
(n = 205) 41
59
89
0.68±0.07
41
59
89
0.68±0.07
42
58
93
0.67±0.09
42
58
93
0.67±0.09
42
58
93
0.67±0.08
42
58
93
0.67±0.08
PP
Baseline Characteristics - Angiographic Profile -
0.980
0.980
0.312
0.984
0.980
0.980
0.312
0.984
![Page 13: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/13.jpg)
Major Adverse Cardiac Events
- 10-Year Follow-Up -
OutcomesOutcomes
Primary Endpoints, (%)Primary Endpoints, (%)
Overall Mortality, (%)Overall Mortality, (%)
Myocardial Infarction, (%)Myocardial Infarction, (%)
Aditional Intervention, (%)Aditional Intervention, (%)
OutcomesOutcomes
Primary Endpoints, (%)Primary Endpoints, (%)
Overall Mortality, (%)Overall Mortality, (%)
Myocardial Infarction, (%)Myocardial Infarction, (%)
Aditional Intervention, (%)Aditional Intervention, (%)
MT
(n = 203)
MT
(n = 203)
CABG
(n = 203)
CABG
(n = 203)
PCI
(n = 205)
PCI
(n = 205)
59.1
31
20.7
39.4
59.1
31
20.7
39.4
33
25.1
10.3
7.4
33
25.1
10.3
7.4
42.4
24.1
13.3
41.9
42.4
24.1
13.3
41.9
PP
0.089 0.089
<0.001
0.010
0.001
![Page 14: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/14.jpg)
Treatment GroupTreatment GroupTreatment GroupTreatment Group InitialInitialInitialInitial 6 Year6 Year6 Year6 Year3 Year3 Year3 Year3 Year 205205
203203
203203
205205
203203
203203
164164
168168
159159
164164
168168
159159
189189
184184
179179
189189
184184
179179
10 Year10 Year10 Year10 Year156156
152152
140140
156156
152152
140140
PCIPCI
CABGCABG
MTMT
PCIPCI
CABGCABG
MTMT
Overall Mortality-Free Survival
![Page 15: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/15.jpg)
Treatment GroupTreatment GroupTreatment GroupTreatment Group InitialInitialInitialInitial 6 Year6 Year6 Year6 Year3 Year3 Year3 Year3 Year
203203
205205
203203
203203
205205
203203
155155
130130
121121
155155
130130
121121
175175
147147
140140
175175
147147
140140
10 Year10 Year10 Year10 Year
150150
108108
9393
150150
108108
9393
CABGCABG
PCIPCI
MTMT
CABGCABG
PCIPCI
MTMT
Ten-Year Follow-up Event-free Survival
![Page 16: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/16.jpg)
End Point and Treatment Allocation
- CABG vs MT -
![Page 17: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/17.jpg)
End Point and Treatment Allocation
- CABG vs PCI -
![Page 18: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/18.jpg)
End Point and Treatment Allocation
- PCI vs MT -
![Page 19: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/19.jpg)
Multivariate Analysis for Treatment Allocation
Primary end pointsPrimary end points
TreatmentTreatment
PCI/CABGPCI/CABG
MT/CABGMT/CABG
Primary end pointsPrimary end points
TreatmentTreatment
PCI/CABGPCI/CABG
MT/CABGMT/CABG
1.461.46
2.292.29
1.06-2.021.06-2.02
1.69-3.101.69-3.10
1.06-2.021.06-2.02
1.69-3.101.69-3.10
MultivariateMultivariate
HRHR
MultivariateMultivariate
HRHR
<0.001 <0.001
0.0210.021
<0.001<0.001
<0.001 <0.001
0.0210.021
<0.001<0.001
VariablesVariables pppp95% CI95% CI95% CI95% CI
Overall DeathOverall Death
TreatmentTreatment
PCI/CABGPCI/CABG
MT/CABGMT/CABG
Overall DeathOverall Death
TreatmentTreatment
PCI/CABGPCI/CABG
MT/CABGMT/CABG
0.970.97
1.291.29
0.970.97
1.291.29
0.65-1.440.65-1.44
0.89-1.870.89-1.87
0.65-1.440.65-1.44
0.89-1.870.89-1.87
0.241 0.241
0.8780.878
0.1750.175
0.241 0.241
0.8780.878
0.1750.175
![Page 20: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/20.jpg)
Multivariate Analysis for Treatment Allocation
Myocardial Infarction
Treatment
PCI/CABG
MT/CABG
Myocardial Infarction
Treatment
PCI/CABG
MT/CABG
2.90
2.69
2.90
2.69
1.39-6.01
1.30-5.60
1.39-6.01
1.30-5.60
Multivariate
HR
Multivariate
HR
0.012
0.004
0.008
0.012
0.004
0.008
VariablesVariables pp95% CI95% CI
Additional Intervention
Treatment
PCI/CABG
MT/CABG
Additional Intervention
Treatment
PCI/CABG
MT/CABG
3.71
7.58
3.71
7.58
1.82-7.52
3.88-14.81
1.82-7.52
3.88-14.81
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
![Page 21: Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies](https://reader035.vdocuments.mx/reader035/viewer/2022062719/56649ec95503460f94bd794c/html5/thumbnails/21.jpg)
CONCLUSION
• All three therapeutic regimens yielded similar and relatively low
rates of overall mortality.
• Compared with CABG, angioplasty was associated with elevated
rate of myocardial infarction and need for revascularization.
• Medical therapy showed significant incidence of myocardial
infarction and high rate of additional revascularization.